CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
March 18, 2020
CCTG Annual Spring Meeting for 2020 has been cancelledPublished: March 18, 2020Category: Office of the Director  CCTG has continued to monitor the developments pertaining to the coronavirus (COVID-19). Read More |
March 13, 2020
CCTG Spring meeting update - coronavirus (COVID-19)Published: March 13, 2020Category: Group updates CCTG has continued to monitor the developments pertaining to the coronavirus (COVID-19). After careful consideration and evaluation of available information at this time, and out of an abundance of caution for the entire network, the CCTG Annual Spring Meeting for 2020 is cancelled. Read More |
March 10, 2020
CCTG Spring meeting update regarding coronavirus (COVID-19)Published: March 10, 2020Category: CCTG Bulletin CCTG Network Members, CCTG is actively monitoring the continuing developments pertaining to the coronavirus (COVID-19) . This includes reviewing reliable sources of information nationally and internationally as well as tracking travel restrictions. We are evaluating risks to patient safety, trial conduct and integrity, as well as critical meetings and engagement activities across the network. Safety and security are our top priorities as we review the situation. Read More |
March 04, 2020
 The purpose of this study was to find the highest dose of durvalumab or of durvalumab with tremelimumab that can be tolerated without causing very severe side effects when receiving standard chemotherapy and to see what effects the study drugs has on this type of cancer. Read More |
 Trial closures for BR16 (NCT00008385) trial: Phase III Chemoprevention Trial of Selenium Supplementation in Persons With Resected Stage 1 Non-Small Cell Lung Cancer and IND222 ( NCT02619864) A Phase I Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients with Previously Treated Glioblastoma Multiforme. Read More |
February 19, 2020
 The CCTG Annual Spring Meeting of Participants is almost here, if you are planning meetings and/or attending the Spring Meeting here is some information you should know! Read More |
Support for annual conference attendance - Frances A Shepherd AwardPublished: February 19, 2020Category: Group updates  Applicants who have had their research accepted for oral or poster presentation at an international scientific meeting and have not received another award to support their travel are eligible to apply. Spring application deadline is March 27, 2020 Read More |
 CCTG Patient Representative Bob Taylor discusses the importance of having somebody, that's not the clinical researcher, representing what patients care about and considering the interests of the patients and their family in clinical trial design. Read More |